U.S. Stock Insider Trading | AtriCure disclosed one report of a company insider’s transaction on March 12

K-LinePoet · 2026-04-07T06:25:06+00:00

On March 12, 2026, AtriCure disclosed that Director WHITE ROBERT S. purchased 10k shares at a price of $14.99 on March 10. Recently, several executives also sold shares on March 1, totaling several million dollars. AtriCure specializes in cardiac devices and postoperative pain management, with products sold in multiple countries.

K-LinePoet

2026-04-07 06:25:06

Abstract generation in progress

March 12, 2026, AtriCure (ATRC) disclosed 1 reportable insider transaction. Director WHITE ROBERT S. purchased 10,000 shares on March 10, 2026.

[Recent Insider Trades]

Filing Date	Position	Name	Trade Date	Buy/Sell	Shares	Price per Share/US$	Total Value/US$
March 12, 2026	Director	WHITE ROBERT S.	March 10, 2026	Buy	10,000	14.99	149,900
March 3, 2026	Executive Officer	Dahlquist Karl S.	March 1, 2026	Sell	15,700	31.26	490,400
March 3, 2026	Executive Officer	Seith Douglas J	March 1, 2026	Sell	22,900	31.26	717,400
March 3, 2026	Executive Officer	Doraiswamy Vinayak	March 1, 2026	Sell	15,600	31.26	487,200
March 3, 2026	Executive Officer	Wirick Angela L	March 1, 2026	Sell	23,000	31.26	717,900
March 3, 2026	Director	CARREL MICHAEL H	March 1, 2026	Sell	72,800	31.26	2,275,000
March 3, 2026	Executive Officer	Privitera Salvatore	March 1, 2026	Sell	13,100	31.26	410,400
March 3, 2026	Executive Officer	Noznesky Justin J	March 1, 2026	Sell	15,600	31.26	487,200
January 2, 2026	Executive Officer	Seith Douglas J	December 31, 2025	Buy	257	27.37	7034.09
November 26, 2025	Director	WEHRWEIN SVEN	November 25, 2025	Sell	4,967	38.00	188,700

[Company Profile]

AtriCure, Inc. was incorporated in Delaware on October 31, 2000. The company is a leading innovator in surgical treatments and therapies for atrial fibrillation, left atrial appendage management, and post-operative pain management. The company’s cardiac ablation and left atrial appendage management products are used by physicians in open-heart and minimally invasive surgeries. The company’s pain management solutions are used by physicians to freeze nerves during cardiac, thoracic, or amputation surgeries. The company’s cryoICE cryoablation ball and cryoXT probes for pain management can temporarily relieve post-operative pain, allowing patients’ bodies to heal after surgery while enabling nerve regeneration and recovery of sensation. The company sells its products to medical centers through its direct sales teams in the United States, Germany, France, the United Kingdom, the Benelux Economic Union region, Australia, and Canada. The company also sells its products through distributors, and those distributors then sell the products to medical centers in other international markets.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.